Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Halozyme’s recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.

Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after ...

Return on Assets (ROA): Halozyme Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (LSE:0J2O) from Market Perform to Underperform. As of May 7, 2025, the average one-year ...

The stock has declined 10.3% in the past year. Halozyme Therapeutics, a biopharmaceutical company, carries a Zacks Rank #2 and has a VGM Score of A. HALO has a trailing four-quarter earnings ...

The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Leerink Partners, and Halozyme Therapeutics downgraded their underperform rating. The last upgrade for Halozyme ...

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...